Pharmacoepidemiological analysis of neuroprotective drugs: state of the problem and perspectives

Gantsgorn E. V.
Department of Pharmacology and Clinical Pharmacology; assistant¹, PhD

Chernigovets L. F.
Department of Epidemiology; assistant professor¹, PhD.

1 - Rostov State Medical University, Rostov–on–Don

The article presents results of literature analysis on the possible applications of neuroprotective drugs and results of modern pharmacoepidemiological studies of those drugs. Conclusions are made about the feasibility of an in-depth pharmacoepidemiological analysis of polyvalent neuroprotective drugs, including antioxidant melatonin (from the group of antioxidants), to extend their application in clinical practice.

pharmacoepidemiological analysis, neuroprotective drugs, melatonin

1. Abakumova, M. A. Analysis of Consumption and Optimization of Provision of Nootropic Drugs to the Population Nootropic Drugs at the Regional Level. PhD thesis, Pharmacology. Pyatigorsk, 2011. 1-23.

2. Arushanyan, E. B. «The Protective Role of Melatonin in Cerebral Circulation Disorders.» Rus. Med. Zhurn. (Nevrologiya) 18, no. 6 (2010): 57-61.

3. Belenichev, I. F. Rational Neuroprotection. Donetsk: Zaslavsky A.J., 2009.

4. Bojcov, S. A. «Lyubertsy Study of Mortality in Patients after Stroke or Transient Ischemic Attack (LIS-2). Design and Evaluation of Drug Therapy.» Racionalnaya Farmakoterapiya v Kardiologii 9, no. 2 (2013): 114-22.

5. Vashchenko, A. A. «Pharmacoepidemiological Analysis of Drugs Recommended to Patients with Cerebral Infarction at Discharge from Hospital.» Byulleten Medicinskih Internet‐konferencij 4, no. 4 (2014): 793.

6. Voronina, T. A. «Hypoxia and Memory. Features of the Application and Effects of Nootropics.» Vestn. RAMN, no. 9 (2000): 531-37.

7. Gancgorn, E. V. Comprehensive Analysis of the Neuroprotective Activity of Nootropics and Their Combinations with Melaksenom in Experimental Brain Ischemia. PhD thesis. Rostov-na-Dony, 2013. 1-264.

8. Gusev, E. I., A. N. Konovalov, V. I. Skvorcova, and A. B. Gekht. Neurology. National Guidelines. Moscow: GEOTAR-Media, 2009.

9. Dovgun, S. S. «The Frequency of Application and the Structure of Prescription of the Neuroprotective Drugs in the Treatment of Acute Stroke.» Sovremennye Problemy Nauki I Obrazovaniya, no. 3 (2012). Assessed at: www.science-education.ru/103-6039.

10. Egorov, K. A. «Analysis of the Regional Pharmaceutical Market of Drugs Used in Acute Cerebral Circulatory Disorders.» Sovremennye Problemy Nauki I Obrazovaniya, no. 3 (2014).

11. Isajkin, A. I. «Pathogenic Aspects of Ischemic Stroke Treatment.» Trudnyj Pacient 8, no. 4 (2010): 21-24.

12. Korzun, A. I. «Stroke Treatment: Nootropics or Evidence-based Medicine ?!» www.hospsurg.ru. 2002. http://www.hospsurg.ru/angiohirurgiya/lechenie-insulta-nootropy-ili-dokazatelnaya-meditsina.html.

13. Kulikov, A. Y. «Pharmacoeconomic Analysis of Neuroprotective Drugs in the Treatment of Acute Stroke.» Farmakoehkonomika 6, no. 3 (2013): 17-22.

14. Miheeva, N. V. Pharmacoepidemiological and Pharmacoeconomic Analysis of Drugs Used for the Pharmacotherapy of Brain Infarction. PhD thesis. Volgograd, 2015. 1-25.

15. Nepolkanov, B. P. «Research Methodology in the Field of Health Technology Assessment: Focus on Pharmacoepidemiology.» In Proceedings of IX IInternational Scientific and Practical Conference, Nauchnye Issledovaniya: Ot Teorii K Praktike, Cheboksary. 3rd ed. Vol. 9. CNS «Interaktiv Plyus», 2016: 58-63.

16. Odinak, M. M. «Modern Possibilities of Stroke Therapy. Aim – Neuroprotection.» Obozrenie Psihiatrii I Medicinskoj Psihologii, no. 4 (2012): 98-102.

17. Ostrovaya, T. V. «Tserebroprotektsiya in the Aspect of Evidence-based Medicine.» Medicina Neotlozhnyh Sostoyanij 9, no. 2 (2007): 48-53.

18. Ostrovskaya, V. O. «Evaluation of Clinical Practice: The Treatment of Patients with Acute Stroke.» Lekarstvennyj Vestnik 6, no. 46 (2012): 31-38.

19. Ratmanova, A. S. «Ischemic Stroke and Neuroprotection: The Search Continues.» Medicine Review, no. 3 (2008): 38-44.

20. Rachina, S. A. «Pharmacoepidemiology, from Theoretical Foundations to Practical Application.» Farmakoehkonomika. Sovremennaya Farmakoehkonomika I Farmakoehpidemiologiya 1, no. 7 (2014): 33-39.

21. Rumyanceva, S. A. «Methods for Rational Pharmaceutical Correction and Secondary Prevention of Vasospasm and Ischemia in Patients with Impaired Cerebral Circulation of Different Nature.» Trudnyj Pacient 8, no. 6-7 (2010): 19-25.

22. Skvorcova, V. I. «Formation of a Health Care System for Patients with Cerebral Stroke in the Russian Federation.» In. Proceedings of All-Russian Scientific and Practical Conference Improving the Provision of Medical Care to Patients with Cardiovascular Diseases. Moscow: Real Taim, 2011: 13-33.

23. Habriev, R. U. «Pharmacoepidemiological Analysis of Pharmacotherapy in Patients with Cerebral Infarction in the Republic of Tatarstan.» Farmakoehkonomika: Teoriya I Praktika 2, no. 1 (2014): 67.

24. Yagudina, R. I. «Development of Pharmacoeconomics and Pharmacoepidemiology in Russia.» Vestnik Roszdravnadzora, no. 2 (2009): 68-71.

25. Furie, K. L. et al. «Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation: A Science Advisory for Healthcare Professionals From the American Heart Association/American Stroke Association.» Stroke 43, no. 12 (2012): 3442-453. doi:10.1161/str.0b013e318266722a.

26. Kernan, W. N. et al. «Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.» Stroke 45, no. 7 (2014): 2160-236. doi:10.1161/str.0000000000000024.

27. Meyers, Juliana L., Keith L. Davis, and Yanni F. Yu. «Stroke and Transient Ischemic Attack in the Long-Term Care Setting: Patient Characteristics, Medication Treatment, and Length of Stay.» The Consultant Pharmacist 26, no. 3 (2011): 170-81. doi:10.4140/tcp.n.2011.170.

28. Pandi-Perumal, S. R., and Daniel P. Cardinali. Melatonin: Biological Basis of Its Function in Health and Disease. Georgetown, TX: Landes Bioscience, 2006.

29. Reiter, R. J., D.-X. Tan, and L. C. Manchester. «Melatonin Defeats Neurally Derived Free Radicals and Reduces the Associated Neuromorphological and Neurobehavioral Damage.» J. Physiol. Pharmacol 58, no. 6, (2007): 5-22.

30. Seidel, G., P. Hermanek, P. Kolominsky-Rabas, C. Matthis et al. «The Quality of Acute Stroke Care – an Analysis of Evidence-Based Indicators in 260 000 Patients.» Deutsches Ärzteblatt International 111, no. 45 (2014): 759-65.

31. Soriento, Y. E. Melatonin, Sleep and Insomnia: Еndocrinology Research and Clinical Developments. New York: Nova Biomedical Books, 2010.

32. Strom, B. L. Pharmacoepidemiology. New York: John Wiley & Sons, 2000.

33. Suruki R.Y., Chan K.A. Basic Pharmacoepidemiology Methods. In Hartzema, A. G., H. H. Tilson, and K. A. Chan editors. Pharmacoepidemiology and Therapeutic Risk Assessment. Cincinatti: Harwey Whitney Books, 2008.

34. Watson, R. R. Melatonin in the Promotion of Health. Taylor & Francis Group LLC, 2012.